Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 2 Trials for Cladribine (DB00242)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03589729Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersSupportive Care